Biotech Co.*
(Country;
Symbol)

Pharma Co.
(Country)

Product

Terms/Details (Date)


Agenix Inc.
(Australia;
ASX: AGX)

Diosynth Biotechnology (unit of NV Organon)

Diosynth will manufacture ThromboView for Phase III trials and commercial sale

The product uses radiolabeled antibodies to locate blood clots in the body; terms of the deal were not disclosed (8/10)

Allos
Therapeutics
Inc.
(ALTH)

Hovione (Portugal)

Deal under which Hovione will manufacture Efaproxyn bulk drug substance

The Phase III product is designed to sensitize hypoxic areas of tumors during radiation; the deal covers both pre- and post- commercialization needs (6/16)

AlphaVax Inc.*

Greer Laboratories

AlphaVax assumed direct responsibility for vaccine manufacturing under a new lease agreement with Greer

AlphaVax will use Greer's vaccine production facility, and will employ several Greer staff who are involved in making AlphaVax vaccines; terms were not disclosed (6/23)

Ark
Therapetuics
Group plc
(UK; LSE:AKT)

BL&H Co. Ltd. (South Korea)

BL&H got rights in South Korea to the wound-healing product Kerraboot

Ark would get a double-digit royalty on sales in the covered territory (6/14)

Avantogen
Ltd.
(Australia;
ASX:ACU)

Dr. Reddy's Laboratories (India)

Deal for the production of Avantogen's GPI-100 adjuvant

Dr. Reddy's will manufacture the product under undisclosed terms (6/23)

BioDiscovery
Inc.*

Tecan Schweiz AG (Switzerland)

Collaboration to develop a data-management solution for interpreting microarray data

They will integrate technologies in the deal, terms of which were not disclosed (6/29)

Co.don AG*
(Germany)

Bioengi Ltd. (Italy)

Bioengi will market Co.don's products for treating osteo-arthritic knee joints and degenerated intervertebral discs

The products are co.don chondrotrans-plant, co.don chondrosphere and co.don chondrotranspant DISC; terms of the deal were not disclosed (6/8)

Cortex
Biochem Inc.*

Bouty SpA (Italy)

Bouty got rights to market Cortex's MagaZorb Nucleic Acid Isolation Kits and associated reagents in Italy

The exclusive distribution deal includes Bouty's biotechnology division, Techno-genetics Srl; terms of the deal were not disclosed (6/14)

DOR
BioPharma Inc.
(AMEX:DOR)
BT-VACC

Dowpharma

Dow will provide process development services for DOR's oral botulinum vaccine,

Dow will use its Pseudomonas-based Pfenex Expression Technology in the effort; terms of the deal were not disclosed (7/26)

GeneGo Inc.*

Rosetta Biosoftware (unit of Merck & Co. Inc.)

Deal to establish interoperability between Rosetta's Resolver system and GeneGo's MetaCore system

Researchers will be able to exchange data between the systems for analyzing gene expression data and for pathway analysis; terms were not disclosed (7/18)

Gene Logic
Inc.
(GLGC)

GE Healthcare

Deal under which GE will distribute Gene Logic's Sciantis System worldwide

The product is an an online gene expression analysis system; terms of the deal were not disclosed (7/19)

Generex
Biotechnology
Corp.
(Canada;
GNBT)

MedGen Corp. (Lebanon)

MedGen got marketing rights to the diabetes product Oral-lyn in Lebanon

MedGen made an up-front license payment and is obligated to certain minimum purchases of the product from Generex (6/16)

Iconix
Pharmaceuticals
Inc.*

Rosetta Biosoftware (unit of Merck & Co. Inc.)

Deal to establish inter-operability between their systems

The deal involves Rosetta's Resolver system and Iconix's DrugMatrix Informatics system; terms were not disclosed (6/20)

Immuno-
Designed
Molecules SA*
(France)

Cambridge Laboratories Ltd. (UK)

CLL got marketing rights to Junovan (Mepact or L-MTP-PE), a Phase III cancer product, in the UK and Ireland

IDM gets an up-front license fee and is entitled to milestone payments, as well as royalties on any resulting sales (6/21)

Iomai Corp.*

The Dow Chemical Co.

Iomai will use the Pfenex Expression Technology from Dowpharma to produce heat labile enterotoxin

Iomai will use the technology to produce a component of its platform for the delivery of vaccines to the skin; terms were not disclosed (6/24)

Lantibio Inc.*

Apotex
Fermentation Inc. (Canada)

Apotex will supply and help in the development of Lantibio's Moli1901 product

The product is being developed for dry-eye syndrome and cystic fibrosis; Apotex is entitled to royalty payments (8/15)

Microbix
Biosystems
Inc.
(Canada;
TSE:MBX)

Undisclosed vaccine producer

They extended by 90 days a deal to evaluate Microbix's technology to boost the production yield of flu vaccine

The initial evaluation period was to expire June 30; terms of the deal were not disclosed (6/24)

Morphotek
Inc.*

Baxter Healthcare Corp.

They expanded existing deal to include manufacturing of Morphotek's Phase I cancer antibody MORAb-003

Baxter already was manufacturing MORAb- 009 and MORAb- 04; terms of the deal were not disclosed (6/30)

Neurobiological
Technologies
Inc.
(NTII)

Nordmark Arzneimittel GmbH & Co KG (Germany) and Baxter Pharmaceutical Solutions LLC

Deal for the manufacturing and packaging of NTI's Viprinex (ancrod) for Phase III trials in acute ischemic stroke

Nordmark will manufacture the biological active ingredient, and Bayer will fill and package the product; terms of the deal were not disclosed (6/27)

Osiris
Therapeutics
Inc.*

JCR Pharmaceuticals Co. Ltd. (Japan)

JCR got rights in Japan to sell stem cells for use in drug screening and evaluation

The deal is an expansion of a license agreement under which JCR got rights to a stem cell drug for treating grafts-host disease (8/4)

Physiomics plc
(UK; AIM:PYC)

Bayer
Technology Services GmbH (germany)

Physiomics will distribute Bayer's PK-Sim pharmaco-kinetic modeling products and services

Terms of the exclusive, renewable five-year deal were not disclosed (6/23)

QBI Life
Sciences
(unit of
Quintessence
Biosciences Inc.)

Takara Bio Inc. (Japan)

Takara will distribute QBI's tools for membrane proteins in Japan, China and Korea

Terms of the deal were not disclosed (7/18)

VaxGen Inc.
(PK:VXGN)

Bristol-Myers Squibb Co.

VaxGen's joint venture Celltrion will manufacture biologic products being developed by BMS

Celltrion, in South Korea, was established by Vaxgen and three South Korean partners; terms of the deal were not disclosed (6/21)

Verus
Pharmaceuticals
Inc.*

Hollister-Stier Laboratories LLC

Verus acquired exclusive, worldwide rights to the approved product Twinject

Twinject is an epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis); it also got rights to other technology and development programs (7/6)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; ASX = Australian Stock Exchange; AMEX = American Stock Exchange; LSE = London Stock Exchange; PK = Pink Sheets; TSE = Toronto Stock Exchange.

No Comments